CS
AGRX

Credit Suisse’s Agile Therapeutics AGRX Stock Holding History

Credit Suisse’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9
Closed -$23K – 4614
2021
Q2 		$23K Buy
+9
New +$29.7K ﹤0.01% 4420
2021
Q1 		– Sell
-11
Closed -$64K – 4650
2020
Q4 		$64K Buy
+11
New +$64.7K ﹤0.01% 4226
2020
Q2 		– Sell
-24
Closed -$90K – 4204
2020
Q1 		$90K Sell
24
-60
-71% -$344K ﹤0.01% 3847
2019
Q4 		$418K Buy
+84
New +$293K ﹤0.01% 3660
2017
Q3 		– Sell
-19
Closed -$142K – 4283
2017
Q2 		$142K Buy
+19
New +$132K ﹤0.01% 3683

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Credit Suisse's AGRX Position: Q3 2021 in Review

Credit Suisse sold out of Agile Therapeutics (AGRX) in Q3 2021, closing a stake of 9 shares — an estimated $23K sold.

Credit Suisse first reported a position in AGRX in Q2 2017 and held it in 5 quarters. The position peaked at $418K in Q4 2019. 49 funds tracked by Wall St. Rank hold AGRX as of Q3 2021.

  • Credit Suisse reported no remaining Agile Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Credit Suisse sold 9 Agile Therapeutics shares in Q3 2021, an estimated $23K.
  • Credit Suisse first reported a position in Agile Therapeutics in Q2 2017 and held it in 5 quarters.
  • Credit Suisse's Agile Therapeutics position peaked at $418K in Q4 2019.
  • 49 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2021.

Based on Credit Suisse's 13F filing for Q3 2021, filed 12 Nov 2021.